872 related articles for article (PubMed ID: 34711976)
1. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial.
Nassif ME; Windsor SL; Borlaug BA; Kitzman DW; Shah SJ; Tang F; Khariton Y; Malik AO; Khumri T; Umpierrez G; Lamba S; Sharma K; Khan SS; Chandra L; Gordon RA; Ryan JJ; Chaudhry SP; Joseph SM; Chow CH; Kanwar MK; Pursley M; Siraj ES; Lewis GD; Clemson BS; Fong M; Kosiborod MN
Nat Med; 2021 Nov; 27(11):1954-1960. PubMed ID: 34711976
[TBL] [Abstract][Full Text] [Related]
2. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial.
Kosiborod MN; Jhund PS; Docherty KF; Diez M; Petrie MC; Verma S; Nicolau JC; Merkely B; Kitakaze M; DeMets DL; Inzucchi SE; Køber L; Martinez FA; Ponikowski P; Sabatine MS; Solomon SD; Bengtsson O; Lindholm D; Niklasson A; Sjöstrand M; Langkilde AM; McMurray JJV
Circulation; 2020 Jan; 141(2):90-99. PubMed ID: 31736335
[TBL] [Abstract][Full Text] [Related]
3. Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials.
McMurray JJV; Docherty KF; de Boer RA; Hammarstedt A; Kitzman DW; Kosiborod MN; Maria Langkilde A; Reicher B; Senni M; Shah SJ; Wilderäng U; Verma S; Solomon SD
Circulation; 2024 Mar; 149(11):825-838. PubMed ID: 38059368
[TBL] [Abstract][Full Text] [Related]
4. Effects of dapagliflozin and empagliflozin on 6-min walk distance in heart failure with preserved and reduced ejection fraction: A systematic review and meta-analysis of randomized controlled trials involving 2624 patients.
Tanashat M; Manasrah A; Abouzid M
Eur J Clin Pharmacol; 2024 Jul; 80(7):951-963. PubMed ID: 38498097
[TBL] [Abstract][Full Text] [Related]
5. Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials.
Nassif ME; Windsor SL; Gosch K; Borlaug BA; Husain M; Inzucchi SE; Kitzman DW; McGuire DK; Pitt B; Scirica BM; Shah SJ; Umpierrez G; Austin BA; Lamba S; Khumri T; Sharma K; Kosiborod MN
Circ Heart Fail; 2023 Jul; 16(7):e009837. PubMed ID: 37203441
[TBL] [Abstract][Full Text] [Related]
6. Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction.
Kosiborod MN; Bhatt AS; Claggett BL; Vaduganathan M; Kulac IJ; Lam CSP; Hernandez AF; Martinez FA; Inzucchi SE; Shah SJ; de Boer RA; Jhund PS; Desai AS; Fang JC; Han Y; Comin-Colet J; Vardeny O; Lindholm D; Wilderäng U; Bengtsson O; McMurray JJV; Solomon SD
J Am Coll Cardiol; 2023 Feb; 81(5):460-473. PubMed ID: 36526515
[TBL] [Abstract][Full Text] [Related]
7. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.
Petrie MC; Verma S; Docherty KF; Inzucchi SE; Anand I; Belohlávek J; Böhm M; Chiang CE; Chopra VK; de Boer RA; Desai AS; Diez M; Drozdz J; Dukát A; Ge J; Howlett J; Katova T; Kitakaze M; Ljungman CEA; Merkely B; Nicolau JC; O'Meara E; Vinh PN; Schou M; Tereshchenko S; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Johanson P; Greasley PJ; Boulton D; Bengtsson O; Jhund PS; McMurray JJV
JAMA; 2020 Apr; 323(14):1353-1368. PubMed ID: 32219386
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial.
Butt JH; Docherty KF; Petrie MC; Schou M; Kosiborod MN; O'Meara E; Katova T; Ljungman CEA; Diez M; Ogunniyi MO; Langkilde AM; Sjöstrand M; Lindholm D; Bengtsson O; Martinez FA; Ponikowski P; Sabatine MS; Solomon SD; Jhund PS; McMurray JJV; Køber L
JAMA Cardiol; 2021 Jun; 6(6):678-689. PubMed ID: 33787831
[TBL] [Abstract][Full Text] [Related]
9. Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the DELIVER Trial.
Peikert A; Chandra A; Kosiborod MN; Claggett BL; Desai AS; Jhund PS; Lam CSP; Inzucchi SE; Martinez FA; de Boer RA; Hernandez AF; Shah SJ; Janssens SP; Belohlávek J; Borleffs CJW; Dobreanu D; Langkilde AM; Bengtsson O; Petersson M; McMurray JJV; Solomon SD; Vaduganathan M
JAMA Cardiol; 2023 Jul; 8(7):684-690. PubMed ID: 37208998
[TBL] [Abstract][Full Text] [Related]
10. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.
Butler J; Shah SJ; Petrie MC; Borlaug BA; Abildstrøm SZ; Davies MJ; Hovingh GK; Kitzman DW; Møller DV; Verma S; Einfeldt MN; Lindegaard ML; Rasmussen S; Abhayaratna W; Ahmed FZ; Ben-Gal T; Chopra V; Ezekowitz JA; Fu M; Ito H; Lelonek M; Melenovský V; Merkely B; Núñez J; Perna E; Schou M; Senni M; Sharma K; van der Meer P; Von Lewinski D; Wolf D; Kosiborod MN;
Lancet; 2024 Apr; 403(10437):1635-1648. PubMed ID: 38599221
[TBL] [Abstract][Full Text] [Related]
11. Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial.
Butler J; Filippatos G; Jamal Siddiqi T; Brueckmann M; Böhm M; Chopra VK; Pedro Ferreira J; Januzzi JL; Kaul S; Piña IL; Ponikowski P; Shah SJ; Senni M; Vedin O; Verma S; Peil B; Pocock SJ; Zannad F; Packer M; Anker SD
Circulation; 2022 Jan; 145(3):184-193. PubMed ID: 34779658
[TBL] [Abstract][Full Text] [Related]
12. Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial.
Kosiborod MN; Verma S; Borlaug BA; Butler J; Davies MJ; Jon Jensen T; Rasmussen S; Erlang Marstrand P; Petrie MC; Shah SJ; Ito H; Schou M; Melenovský V; Abhayaratna W; Kitzman DW;
Circulation; 2024 Jan; 149(3):204-216. PubMed ID: 37952180
[TBL] [Abstract][Full Text] [Related]
13. Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant-level pooled analysis from the DAPA-HF and DELIVER trials.
Bhatt AS; Kosiborod MN; Vaduganathan M; Claggett BL; Miao ZM; Kulac IJ; Lam CSP; Hernandez AF; Martinez F; Inzucchi SE; Shah SJ; de Boer RA; Jhund PS; Desai AS; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
Eur J Heart Fail; 2023 Jul; 25(7):981-988. PubMed ID: 37211977
[TBL] [Abstract][Full Text] [Related]
14. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
Nassif ME; Windsor SL; Tang F; Khariton Y; Husain M; Inzucchi SE; McGuire DK; Pitt B; Scirica BM; Austin B; Drazner MH; Fong MW; Givertz MM; Gordon RA; Jermyn R; Katz SD; Lamba S; Lanfear DE; LaRue SJ; Lindenfeld J; Malone M; Margulies K; Mentz RJ; Mutharasan RK; Pursley M; Umpierrez G; Kosiborod M
Circulation; 2019 Oct; 140(18):1463-1476. PubMed ID: 31524498
[TBL] [Abstract][Full Text] [Related]
15. Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial.
Kosiborod MN; Angermann CE; Collins SP; Teerlink JR; Ponikowski P; Biegus J; Comin-Colet J; Ferreira JP; Mentz RJ; Nassif ME; Psotka MA; Tromp J; Brueckmann M; Blatchford JP; Salsali A; Voors AA
Circulation; 2022 Jul; 146(4):279-288. PubMed ID: 35377706
[TBL] [Abstract][Full Text] [Related]
16. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
McMurray JJV; Solomon SD; Inzucchi SE; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Sabatine MS; Anand IS; Bělohlávek J; Böhm M; Chiang CE; Chopra VK; de Boer RA; Desai AS; Diez M; Drozdz J; Dukát A; Ge J; Howlett JG; Katova T; Kitakaze M; Ljungman CEA; Merkely B; Nicolau JC; O'Meara E; Petrie MC; Vinh PN; Schou M; Tereshchenko S; Verma S; Held C; DeMets DL; Docherty KF; Jhund PS; Bengtsson O; Sjöstrand M; Langkilde AM;
N Engl J Med; 2019 Nov; 381(21):1995-2008. PubMed ID: 31535829
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial.
Butt JH; Adamson C; Docherty KF; de Boer RA; Petrie MC; Inzucchi SE; Kosiborod MN; Maria Langkilde A; Lindholm D; Martinez FA; Bengtsson O; Schou M; O'Meara E; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Jhund PS; McMurray JJV; Køber L
Circ Heart Fail; 2021 Dec; 14(12):e008837. PubMed ID: 34802253
[TBL] [Abstract][Full Text] [Related]
18. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
Kato ET; Silverman MG; Mosenzon O; Zelniker TA; Cahn A; Furtado RHM; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Bonaca MP; Ruff CT; Desai AS; Goto S; Johansson PA; Gause-Nilsson I; Johanson P; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
Circulation; 2019 May; 139(22):2528-2536. PubMed ID: 30882238
[TBL] [Abstract][Full Text] [Related]
19. Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.
Santos-Gallego CG; Vargas-Delgado AP; Requena-Ibanez JA; Garcia-Ropero A; Mancini D; Pinney S; Macaluso F; Sartori S; Roque M; Sabatel-Perez F; Rodriguez-Cordero A; Zafar MU; Fergus I; Atallah-Lajam F; Contreras JP; Varley C; Moreno PR; Abascal VM; Lala A; Tamler R; Sanz J; Fuster V; Badimon JJ;
J Am Coll Cardiol; 2021 Jan; 77(3):243-255. PubMed ID: 33197559
[TBL] [Abstract][Full Text] [Related]
20. Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: a systematic review and meta-analysis.
Chen J; Jiang C; Guo M; Zeng Y; Jiang Z; Zhang D; Tu M; Tan X; Yan P; Xu X; Long Y; Xu Y
Cardiovasc Diabetol; 2024 Jan; 23(1):2. PubMed ID: 38172861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
